 Clarithromycin
"Clarithromycin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A semisynthetic macrolide antibiotic derived from ERYTHROMYCIN that is active against a variety of microorganisms. It can inhibit protein synthesis in bacteria by reversibly binding to the 50S ribosomal subunits. This inhibits the translocation of aminoacyl transfer-RNA and prevents peptide chain elongation.
| Descriptor ID |
D017291
|
| MeSH Number(s) |
D02.540.505.250.100
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Clarithromycin".
Below are MeSH descriptors whose meaning is more specific than "Clarithromycin".
This graph shows the total number of publications written about "Clarithromycin" by people in UAMS Profiles by year, and whether "Clarithromycin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2025 | 0 | 1 | 1 | | 2022 | 0 | 1 | 1 | | 2021 | 1 | 0 | 1 | | 2020 | 1 | 2 | 3 | | 2019 | 1 | 0 | 1 | | 2018 | 1 | 1 | 2 | | 2017 | 1 | 0 | 1 | | 2016 | 0 | 1 | 1 | | 2014 | 0 | 1 | 1 | | 2013 | 1 | 1 | 2 | | 2011 | 0 | 1 | 1 | | 2010 | 0 | 1 | 1 | | 2009 | 1 | 0 | 1 | | 2008 | 1 | 0 | 1 | | 2007 | 0 | 1 | 1 | | 2006 | 1 | 1 | 2 | | 2005 | 0 | 3 | 3 | | 2004 | 0 | 1 | 1 | | 2003 | 0 | 2 | 2 | | 1998 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Clarithromycin" by people in Profiles over the past ten years.
-
Wu PJ, Tsay FW, Wu DC, Yang JC, Chuah SK, Chen KY, Chen CL, Lee CL, Shih CA, Liu YH, Shiu SI, Tai WC, Kuo CH, Lei WY, Kao SS, Tsai TJ, Feng IC, Koseki M, Hsu PI, Sheu MJ. Sequential changes of antibiotic resistances of Helicobacter pylori in Taiwan from 2019 to 2024. World J Gastroenterol. 2025 Oct 21; 31(39):111380.
-
Chuah YY, Wu DC, Chuah SK, Chen KY, Yang JC, Lee CL, Chen CL, Shiu SI, Shie CB, Shih CA, Tsay FW, Liu YH, Hsu PI. REAP-HP survey 2020: Comparing the real-world practice and expectation in Helicobacter pylori eradication of the Taiwanese gastroenterologists in 2015 and 2020. Helicobacter. 2022 Dec; 27(6):e12931.
-
Moon SH, Kaufmann Y, Fujiwara R, Huang E. Enzymatically-crosslinked gelatin hydrogels containing paenipeptin and clarithromycin against carbapenem-resistant pathogen in murine skin wound infection. BMC Microbiol. 2021 11 24; 21(1):326.
-
Chang YL, Tung YC, Tu YK, Yeh HZ, Yang JC, Hsu PI, Kim SE, Wu MF, Liou WS, Shiu SI. Efficacy of second-line regimens for Helicobacter pylori eradication treatment: a systemic review and network meta-analysis. BMJ Open Gastroenterol. 2020 09; 7(1).
-
Moon SH, Kaufmann Y, Huang E. Paenipeptin Analogues Potentiate Clarithromycin and Rifampin against mcr-1-Mediated Polymyxin-Resistant Escherichia coli In Vivo. Antimicrob Agents Chemother. 2020 03 24; 64(4).
-
Erol E, Locke S, Saied A, Cruz Penn MJ, Smith J, Fortner J, Carter C. Antimicrobial susceptibility patterns of Rhodococcus equi from necropsied foals with rhodococcosis. Vet Microbiol. 2020 Mar; 242:108568.
-
Hsu PI, Pan CY, Kao JY, Tsay FW, Peng NJ, Kao SS, Chen YH, Tsai TJ, Wu DC, Tsai KW. Short-term and long-term impacts of Helicobacter pylori eradication with reverse hybrid therapy on the gut microbiota. J Gastroenterol Hepatol. 2019 Nov; 34(11):1968-1976.
-
Huber L, Gigu?re S, Slovis NM, Carter CN, Barr BS, Cohen ND, Elam J, Erol E, Locke SJ, Phillips ED, Smith JL. Emergence of Resistance to Macrolides and Rifampin in Clinical Isolates of Rhodococcus equi from Foals in Central Kentucky, 1995 to 2017. Antimicrob Agents Chemother. 2019 01; 63(1).
-
Moon SH, Huang E. Lipopeptide Paenipeptin Analogues Potentiate Clarithromycin and Rifampin against Carbapenem-Resistant Pathogens. Antimicrob Agents Chemother. 2018 08; 62(8).
-
Moon SH, Zhang X, Zheng G, Meeker DG, Smeltzer MS, Huang E. Novel Linear Lipopeptide Paenipeptins with Potential for Eradicating Biofilms and Sensitizing Gram-Negative Bacteria to Rifampicin and Clarithromycin. J Med Chem. 2017 12 14; 60(23):9630-9640.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|